tiprankstipranks
Trending News
More News >

Fulcrum Therapeutics sees cash runway into at least 2027

As of March 31, 2025, cash, cash equivalents, and marketable securities were $226.6 million, as compared to $241.0 million as of December 31, 2024. The decrease of $14.4 million is primarily due to cash used to fund operating activities in 2025.

Protect Your Portfolio Against Market Uncertainty

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue